Abstract:Since the approval of the first checkpoint inhibitor, ipilimumab (α-CTLA4), there continues to be enthusiasm around leveraging the immune system to eradicate solid tumors. However, unknowns about the cellular mechanism(s) that cause some patients to durably respond while others relapse, continue to stymie the field. To support ongoing efforts elucidating cell subsets responsible for differences in patient responses, we aim to evaluate the functional heterogeneity of T-cell subsets responding to checkpoint inhibitors in mouse models of solid tumors. Single-cell RNA-seq has enabled discoveries of transcriptionally defined cell subsets, but understanding their function require inference from transcription, flow-based validation biased by pre-selection of subsets with specific markers, or reliance on surrogate markers for cell-extrinsic functions (e.g., cytotoxicity). Thus, functional heterogeneity could be obscured. To address this, we leveraged a novel technology that converges live, cellular functions with transcriptomics at the resolution of single cell-cell interactions. This technology captures tens of thousands of individual cells or defined combinations of groups of cells in bio-compatible hydrogel compartments, enabling longitudinal imaging over days to weeks. Throughout this period, functions are characterized via bright-field or immunofluorescence readouts, including antibodies, cytokine capture beads, and dyes. Cells are then lysed within compartments to generate barcoded libraries for mRNA-sequencing and gene signatures from individual cells computationally deconvoluted. With this technology, we developed a novel assay that enables longitudinal, unbiased functional characterization of individual T cells mapped to single-cell transcriptomics. Single mouse primary T cells were encapsulated with one or more MC38 target cells and imaged over time. We validated combinations of different readouts can be measured from the same T-cell, including cell-counts for proliferation, CD8/3 expression to differentiate T cells from target cells, activation markers, and / or target cell death via Sytox. Thus, single T cells can be multi-functionally evaluated over time, enabling the study of attributes inaccessible at high scale with prior technologies, including kinetics of killing or the number of target cells killed by a single T-cell. For assays combining cytotoxicity and surface receptors, we generated barcoded libraries from functionally characterized T cells for sequencing and developed an analytical pipeline that deconvolutes mRNA from single T cells mapped to their multi-functional profiles, to identify novel pathways that regulate anti-tumor functions. We will leverage this workflow to functionally characterize single T cells in tumor-bearing mice treated with checkpoint inhibitors and map the data to underlying transcriptomics. In doing so, we aim to discover functional subsets, potentially with identical transcriptional profiles, to support hypothesis generation around mechanisms governing anti-tumor efficacy of checkpoint inhibitors. Citation Format: Jacqueline Yee, Praveer Sharma, Yunmin Li, Isaac Thomas, Pier F Gherardini, Teresa Ai, Mostafa Ronaghi, Gary Schroth, Matthew H Spitzer. Novel workflow for characterizing T-cell functional heterogeneity in response to checkpoint inhibitors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr A025.

Abstract 5182: Exploiting tumor RNA-sequencing data for prediction of immune checkpoint inhibition response

Abstract 1563: Prediction of immune-checkpoint blockade response in gastrointestinal cancer patients using a machine learning-based RNA signature

Abstract 7620: Immuno-transcriptomic profiling of blood and tumor tissue identifies gene signatures associated with immunotherapy response in metastatic bladder cancer

Abstract 6425: Harnessing big data from pan-cancer concerning more than 1300 patients with immune checkpoint inhibitors identifies novel predictive biomarkers

Abstract 5132: Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of immune checkpoint inhibitor in combination with chemotherapy in advanced unresectable biliary tract cancers

Abstract PR-08: Spatial transcriptomics to profile the non-small cell lung cancer tumor microenvironment and identify novel predictive biomarkers for checkpoint blockade

Abstract A136: Inferring therapeutic vulnerability within tumors through integration of pan-cancer cell line and single-cell transcriptomic profiles

Abstract 4951: Integrative multi-omic machine learning model predicts neoadjuvant immunotherapy response using molecular data and deep learning-derived features from digital pathology

Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature As an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers

Abstract 2036: Multi-omic dissection of immunotherapy response groups in non-small cell lung cancer (NSCLC)

Abstract 5141: Using single cell gene expression to develop treatment response predictions in multiple myeloma

Abstract 6253: Single-cell RNA sequencing reveals metastatic site-specific biomarkers for predicting response to CDK4/6 inhibition in advanced HR+/HER2- breast cancer

Abstract 578: Prediction of PD-1 treatment outcome in mismatch repair deficient metastatic colorectal cancer using a multi-omic approach

Abstract 849: Evaluation of a transcriptomics-based precision oncology platform for patient-therapy alignment in treatment resistant malignancies

Abstract B077: Signatures of T-cell dysfunction and exclusion predict cancer immunotherapy response

Abstract 900: Development and validation of an artificial-intelligence-based pathomics biomarker to predict resistance to first-line treatment in metastatic colorectal cancer

Abstract A025: Novel workflow for characterizing T-cell functional heterogeneity in response to checkpoint inhibitors

Abstract PO3-15-05: B cell immunology predict response and survival in PD-1/PD-L1 targeting immune checkpoint inhibition of metastatic breast cancer

Abstract 6397: Immune profiling for improving responsiveness to ipilimumab plus nivolumab checkpoint blockade treatment in patients with metastatic melanoma

Abstract 5955: in Silico Dissection of Immune Infiltrate Signatures That Are Detected by DetermaIO, a Predictor of Response to Immune Therapy

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients